Sponsored

Chimeric Therapeutics (ASX: CHM) shares soar 70% on FDA IND clearance for CHM 2101

October 31, 2023 12:00 PM AEDT | By Sonal Goyal
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • CHM has gained the FDA approval for its IND application for CHM 2101.
  • Patient enrolment for the Phase 1A clinical trial is expected to begin in 2024.
  • The study will focus on gastrointestinal cancers.

Chimeric Therapeutics Limited (ASX: CHM) has reported another milestone, receiving approval from the US FDA for its Investigational New Drug (IND) application.

The latest development concerns CHM 2101, which is a third-generation CDH17 CAR T cell therapy targeting gastrointestinal cancers, including neuroendocrine tumours, gastric cancer and colorectal cancer.

With this development, the company can commence its Phase 1A/B clinical trial. Patient enrolment for the multi-centre, open label study is expected to start in 2024.

CHM share price jumps over 70%

CHM shares jumped 73.08% to trade at AU$0.045 apiece early morning on October 2023, with a market cap of AU$13.88 million. The stock closed the day’s trade at AU$0.031.

About CHM 2101 clinical program

The CHM 2101 clinical program is based on the preclinical study, which was published in March 2022 in the preeminent scientific journal – Nature Cancer. The study was published by Xianxin Hua, MD, PhD, a leading immunotherapy scientist and his team at the University of Pennsylvania.

Data source: Company update


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.